Unlabelled: Troponin I is frequently elevated in sepsis, but optimal clinical approaches to diagnosis and management of troponin I during sepsis are unclear.

Objectives: We aimed to describe the variation in troponin I measurement and the cardiovascular diagnostic and therapeutic approach to elevated troponin I among critically ill adults with sepsis.

Design Setting And Participants: Observational cohort study of the hospital-level variation in serial troponin I measurement, trending troponin I to peak, echocardiography, cardiac stress test, cardiac catheterization, antiplatelet agents, therapeutic anticoagulation, beta-blockers, and statins quantified using hospital median odds ratios-the median odds of receiving an intervention at randomly selected higher versus lower rate hospitals-derived from multivariable-adjusted random-effects logistic regression models with hospital site as the random effect. The Premier Healthcare Database was used. Patients were adults aged greater than 18 years admitted to the ICU with sepsis from 2016 to 2020.

Main Outcomes And Measures: The hospital-level median odds ratios of troponin I measurement as well as cardiovascular diagnostics and therapeutics.

Results: Among 85,830 adults with sepsis, 53,058 (61.8%) had a troponin I measured, with a median odds ratio of troponin measurement across hospitals of 5.30 (95% CI, 4.98-5.67). Among 27,665 adults (32.2%) with sepsis and an elevated troponin I level, 84.8% had serial troponin I measurements, 66.0% had troponin trended to peak level, 66.7% had an echocardiogram, 4.1% had a cardiac stress test, 6.6% underwent cardiac catheterization, 48.3% received antiplatelet agents, 8.3% received therapeutic anticoagulation, 50.5% received beta-blockers, and 38.1% received statins. The median odds ratios between hospitals for cardiovascular diagnostics and therapeutics ranged from 1.28 (95% CI, 1.24-1.32) for use of beta-blockers to 7.58 (95% CI, 6.43-8.77) for use of therapeutic anticoagulation.

Conclusions And Relevance: Both troponin I measurement and the approach to an elevated troponin I among critically ill adults with sepsis varied widely across hospitals consistent with disparate practice and care efficiency. Prospective studies are needed to guide an informed approach to troponin I measurement and cardiovascular evaluation in sepsis.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9833455PMC
http://dx.doi.org/10.1097/CCE.0000000000000842DOI Listing

Publication Analysis

Top Keywords

troponin measurement
28
median odds
20
troponin
16
elevated troponin
16
measurement cardiovascular
12
approach elevated
12
troponin critically
12
critically ill
12
variation troponin
8
sepsis
8

Similar Publications

Background: Astragalus injection has been utilized in traditional Chinese medicine to treat a variety of diseases. The purpose of this systematic review was to evaluate the effectiveness of Astragalus injection in the treatment of viral myocarditis.

Methods: English databases such as PubMed, Cochrane Library, and EMBASE, and Chinese databases of Sino Med, China National Knowledge Infrastructure (CNKI), the VIP Information Resource Integration Service Platform, and Wanfang Data Information Site, were searched from their inception until May 1, 2024.

View Article and Find Full Text PDF

Objectives: Cardiovascular complications are well known in humans with autosomal dominant polycystic kidney disease (PKD), but limited data exist for cats. This study aimed to assess echocardiographic changes, cardiac troponin I (cTnI) levels and systolic blood pressure (SBP) in Persian cats with PKD to detect early cardiac abnormalities.

Methods: In total, 52 Persian and mixed-Persian cats were enrolled, with 26 cats in the control group and 26 diagnosed with PKD via ultrasound due to the unavailability of genetic testing.

View Article and Find Full Text PDF

A Narrative Review of the Role of Blood Biomarkers in the Risk Prediction of Cardiovascular Diseases.

Cureus

December 2024

Public Health Sciences, Scientific Knowledge for Ageing and Neurological Ailments (SKAN) Research Trust, Bengaluru, IND.

Article Synopsis
  • Cardiovascular disease (CVD) is a major global health issue, making it essential to find biomarkers that can detect it early in healthy people to enhance preventive measures and improve overall health outcomes.
  • Various biomarkers, such as atherogenic lipoproteins and inflammatory markers like C-reactive protein (CRP), have shown connections to CVD risk factors, aiding in risk prediction when combined with traditional indicators.
  • Emerging biomarkers like myeloperoxidase (MPO) and procalcitonin (PCT) are being explored for their potential in early detection of systemic infections, emphasizing the importance of identifying the best biomarker combinations for effective diagnosis and risk assessment.
View Article and Find Full Text PDF

Remote ischemic preconditioning (RIPC) is reported to have early-phase and delayed-phase organ-protective effects. Previous studies have focused on the organ protection of a single RIPC protocol, and the clinical outcomes remain uncertain. Whether the modified RIPC (mRIPC) protocol performed repeatedly provides cardiopulmonary protection is still uncertain.

View Article and Find Full Text PDF

An electrochemiluminescence biosensor based on silver-cysteine nanorod as an emitter and AgNP-decorated FeMoO as a signal amplifier for sensitive detection of heart-type fatty acid binding protein.

Mikrochim Acta

December 2024

State Key Laboratory for Chemistry and Molecular Engineering of Medicinal Resources, Key Laboratory for Chemistry and Molecular Engineering of Medicinal Resources (Ministry of Education of China), Collaborative Innovation Center for Guangxi Ethnic Medicine, School of Chemistry and Pharmaceutical Sciences, Guangxi Normal University, Guilin, 541004, China.

An electrochemiluminescence (ECL) immunosensor was developed for the highly sensitive and specific detection of heart-type fatty acid binding protein (H-FABP) and the rapid diagnosis of acute myocardial infarction (AMI). H-FABP is a biomarker that is highly specific to cardiac tissue and is associated with a range of cardiac diseases. Following myocardial injury, the rate of increase in H-FABP levels is greater than that observed for myoglobin and troponin.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!